Oskar Ragnarsson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7278725/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	9.0	455
2	Improved Cortisol Exposure-Time Profile and Outcome in Patients with Adrenal Insufficiency: A Prospective Randomized Trial of a Novel Hydrocortisone Dual-Release Formulation. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 473-481.	3.6	286
3	The incidence rate of pituitary adenomas in western Sweden for the period 2001–2011. European Journal of Endocrinology, 2014, 171, 519-526.	3.7	226
4	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	3.7	196
5	Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1689-1698.	3.6	142
6	MECHANISMS IN ENDOCRINOLOGY: Cushing's syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. European Journal of Endocrinology, 2015, 173, R1-R14.	3.7	141
7	Systematic review of surgery and outcomes in patients with primary aldosteronism. British Journal of Surgery, 2015, 102, 307-317.	0.3	102
8	Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary, 2019, 22, 422-434.	2.9	95
9	Long-Term Cognitive Impairments and Attentional Deficits in Patients with Cushing's Disease and Cortisol-Producing Adrenal Adenoma in Remission. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1640-E1648.	3.6	86
10	Overall and Disease-Specific Mortality in Patients With Cushing Disease: A Swedish Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2375-2384.	3.6	83
11	Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. European Journal of Endocrinology, 2018, 178, 459-469.	3.7	72
12	Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. European Journal of Endocrinology, 2020, 182, 523-531.	3.7	59
13	Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. European Journal of Endocrinology, 2017, 177, 251-256.	3.7	57
14	The incidence of endogenous Cushing's syndrome in the modern era. Clinical Endocrinology, 2019, 91, 263-270.	2.4	53
15	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	3.7	53
16	Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1183-e1194.	3.6	48
17	The incidence of Cushing's disease: a nationwide Swedish study. Pituitary, 2019, 22, 179-186.	2.9	46
18	MANAGEMENT OF ENDOCRINE DISEASE: Cushing's syndrome: a structured short- and long-term management plan for patients in remission. European Journal of Endocrinology, 2013, 169, R139-R152.	3.7	45

#	Article	IF	CITATIONS
19	Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. European Journal of Endocrinology, 2014, 171, 369-377.	3.7	45
20	Excess Morbidity Persists in Patients With Cushing's Disease During Long-term Remission: A Swedish Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2616-2624.	3.6	42
21	Body composition and bone mineral density in women with Cushing's syndrome in remission and the association with common genetic variants influencing glucocorticoid sensitivity. European Journal of Endocrinology, 2015, 172, 1-10.	3.7	41
22	Worse Healthâ€Related Quality of Life at longâ€ŧerm followâ€up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <scp>ERCUSYN</scp> . Clinical Endocrinology, 2018, 88, 787-798.	2.4	40
23	The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients. European Journal of Endocrinology, 2014, 171, 571-579.	3.7	38
24	Visceral Fat and Novel Biomarkers of Cardiovascular Disease in Patients With Addison's Disease: A Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4264-4272.	3.6	38
25	Discontinuing Long-Term GH Replacement Therapy—A Randomized, Placebo-Controlled Crossover Trial in Adult GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3185-3195.	3.6	37
26	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	3.7	37
27	Adrenal venous sampling: the learning curve of a single interventionalist with 282 consecutive procedures. Diagnostic and Interventional Radiology, 2018, 24, 89-93.	1.5	36
28	Psychiatric and neurocognitive consequences of endogenous hypercortisolism. Journal of Internal Medicine, 2020, 288, 168-182.	6.0	35
29	Reduced DNA methylation and psychopathology following endogenous hypercortisolism – a genome-wide study. Scientific Reports, 2017, 7, 44445.	3.3	33
30	Long-term safety of once-daily, dual-release hydrocortisone in patients with adrenal insufficiency: a phase 3b, open-label, extension study. European Journal of Endocrinology, 2017, 176, 715-725.	3.7	33
31	Pituitary dysfunction in granulomatosis with polyangiitis. Pituitary, 2017, 20, 594-601.	2.9	32
32	Reference intervals of salivary cortisol and cortisone and their diagnostic accuracy in Cushing's syndrome. European Journal of Endocrinology, 2020, 182, 569-582.	3.7	29
33	Common Genetic Variants in the Glucocorticoid Receptor and the 11β-Hydroxysteroid Dehydrogenase Type 1 Genes Influence Long-Term Cognitive Impairments in Patients With Cushing's Syndrome in Remission. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1803-E1807.	3.6	28
34	Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease. European Journal of Endocrinology, 2010, 162, 677-684.	3.7	27
35	Glucocorticoid replacement therapy is independently associated with reduced bone mineral density in women with hypopituitarism. Clinical Endocrinology, 2012, 76, 246-252.	2.4	26
36	Mental Fatigue and Executive Dysfunction in Patients with Cushing's Syndrome in Remission. Behavioural Neurology, 2015, 2015, 1-6.	2.1	26

Oskar Ragnarsson

#	Article	IF	CITATIONS
37	Higher incidence of morbidity in women than men with non-functioning pituitary adenoma: a Swedish nationwide study. European Journal of Endocrinology, 2016, 175, 55-61.	3.7	25
38	Pituitary Metastases: A Nationwide Study on Current Characteristics With Special Reference to Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3379-3388.	3.6	22
39	Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial. ELife, 2021, 10, .	6.0	22
40	Tumoral MGMT content predicts survival in patients with aggressive pituitary tumors and pituitary carcinomas given treatment with temozolomide. Endocrine, 2018, 62, 737-739.	2.3	21
41	Cardiovascular and Metabolic Impact of Glucocorticoid Replacement Therapy. Frontiers of Hormone Research, 2014, 43, 33-44.	1.0	21
42	Decreased prefrontal functional brain response during memory testing in women with Cushing's syndrome in remission. Psychoneuroendocrinology, 2017, 82, 117-125.	2.7	19
43	A polymorphism in the <i>CYP17A1</i> gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome. Clinical Endocrinology, 2017, 87, 433-439.	2.4	19
44	Time trends of mortality in patients with non-functioning pituitary adenoma: a Swedish nationwide study. Pituitary, 2017, 20, 218-224.	2.9	19
45	Ectopic ACTH- and/or CRH-Producing Pheochromocytomas. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 598-608.	3.6	19
46	Radiotherapy as a tool for the treatment of Cushing's disease. European Journal of Endocrinology, 2019, 180, D9-D18.	3.7	18
47	Temporal relationship of sleep apnea and acromegaly: a nationwide study. Endocrine, 2018, 62, 456-463.	2.3	17
48	Adrenal Venous Sampling in Young Patients with Primary Aldosteronism. Extravagance or Irreplaceable?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e2087-e2095.	3.6	17
49	Incidence of malignant tumours in patients with a non-functioning pituitary adenoma. Endocrine-Related Cancer, 2017, 24, 227-235.	3.1	16
50	Increasing Incidence of Primary Aldosteronism in Western Sweden During 3 Decades – Yet An Underdiagnosed Disorder. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3603-e3610.	3.6	16
51	Psychotropic Drugs in Patients with Cushing's Disease Before Diagnosis and at Long-Term Follow-Up: A Nationwide Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1750-1760.	3.6	15
52	Adrenal venous sampling in patients with ACTH-independent hypercortisolism. Endocrine, 2019, 66, 338-348.	2.3	14
53	High prescription rate of oral glucocorticoids in children and adults: A retrospective cohort study from Western Sweden. Clinical Endocrinology, 2020, 92, 21-28.	2.4	14
54	Growth hormone deficiency in adults with hypopituitarism—What are the risks and can they be eliminated by therapy?. Journal of Internal Medicine, 2021, 290, 1180-1193.	6.0	14

#	Article	IF	CITATIONS
55	Cushing's syndrome – Disease monitoring: Recurrence, surveillance with biomarkers or imaging studies. Best Practice and Research in Clinical Endocrinology and Metabolism, 2020, 34, 101382.	4.7	12
56	Elevated resting-state connectivity in the medial temporal lobe and the prefrontal cortex among patients with Cushing's syndrome in remission. European Journal of Endocrinology, 2019, 180, 329-338.	3.7	12
57	Long-term outcomes of patients with acromegaly: a report from the Swedish Pituitary Register. European Journal of Endocrinology, 2022, 186, 329-339.	3.7	12
58	Effect of short-term GH and testosterone administration on body composition and glucose homoeostasis in men receiving chronic glucocorticoid therapy. European Journal of Endocrinology, 2013, 168, 243-251.	3.7	11
59	Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement. European Journal of Endocrinology, 2018, 179, 229-237.	3.7	11
60	Lower ⁶⁸ Gaâ€DOTATOC uptake in nonfunctioning pituitary neuroendocrine tumours compared to normal pituitary gland—A proofâ€ofâ€concept study. Clinical Endocrinology, 2020, 92, 222-231.	2.4	11
61	Incidence of Benign and Malignant Tumors in Patients With Acromegaly Is Increased: A Nationwide Population-based Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3487-3496.	3.6	11
62	High Mortality Rate in Oral Glucocorticoid Users: A Population-Based Matched Cohort Study. Frontiers in Endocrinology, 0, 13, .	3.5	10
63	Prevalence of Nelson's syndrome after bilateral adrenalectomy in patients with cushing's disease: a systematic review and meta-analysis. Pituitary, 2021, 24, 797-809.	2.9	9
64	The Impact of Glucocorticoid Replacement on Bone Mineral Density in Patients With Hypopituitarism Before and After 2 Years of Growth Hormone Replacement Therapy. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1479-1485.	3.6	8
65	The association between urinary cortisol excretion and cardiovascular risk factors, bone status and quality of life in the population. Steroids, 2015, 101, 71-77.	1.8	8
66	Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 814-825.	3.6	8
67	Carpal tunnel syndrome in acromegaly: a nationwide study. European Journal of Endocrinology, 2021, 184, 209-216.	3.7	8
68	Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission. European Journal of Endocrinology, 2013, 169, 211-215.	3.7	7
69	Pre―and postoperative ⁶⁸ Gaâ€ĐOTATOC positron emission tomography for hormoneâ€secreting pituitary neuroendocrine tumours. Clinical Endocrinology, 2021, 94, 956-967.	2.4	7
70	Natural history and surgical outcome of Rathke's cleft cysts—A study from the Swedish Pituitary Registry. Clinical Endocrinology, 2022, 96, 54-61.	2.4	7
71	Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia. Endocrine, 2020, 70, 412-420.	2.3	6
72	MCM7 as a marker of postsurgical progression in non-functioning pituitary adenomas. European Journal of Endocrinology, 2021, 184, 521-531.	3.7	6

#	Article	IF	CITATIONS
73	Metabolic Effects of Cortisone Acetate vs Hydrocortisone in Patients With Secondary Adrenal Insufficiency. Journal of the Endocrine Society, 2020, 4, bvaa160.	0.2	6
74	Extended Support Within a Person-Centered Practice After Surgery for Patients With Pituitary Tumors: Protocol for a Quasiexperimental Study. JMIR Research Protocols, 2020, 9, e17697.	1.0	6
75	The pre- and postoperative illness trajectory in patients with pituitary tumours. Endocrine Connections, 2019, 8, 878-886.	1.9	6
76	Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood. European Journal of Endocrinology, 2012, 166, 593-600.	3.7	5
77	Inadequate testosterone suppression after medical and subsequent surgical castration in a patient with prostate cancer. BMJ Case Reports, 2013, 2013, bcr2013010395-bcr2013010395.	0.5	4
78	Diagnostic value of the water deprivation test in the polyuria-polydipsia syndrome. Hormones, 2018, 16, 414-422.	1.9	4
79	Primary Adrenal Leiomyosarcoma: Clinical, Radiological, and Histopathological Characteristics. Journal of the Endocrine Society, 2020, 4, bvaa055.	0.2	4
80	Increased Mortality Persists after Treatment of Cushing's Disease: A Matched Nationwide Cohort Study. Journal of the Endocrine Society, 2022, 6, bvac045.	0.2	4
81	Successful Treatment with Selpercatinib for Ectopic Cushing's Syndrome Due to Medullary Thyroid Cancer. Current Oncology, 2022, 29, 3494-3498.	2.2	3
82	Urinary free cortisol and androgens in the population—Hormone interactions and the relationship with body composition and bone status. Steroids, 2016, 115, 154-159.	1.8	2
83	Endocrinological diagnosis and replacement therapy for hypopituitarism. , 2021, , 135-146.		2
84	Decreasing mortality and changes in treatment patterns in patients with acromegaly from a nationwide study. European Journal of Endocrinology, 2019, 180, X1-X3.	3.7	2
85	The impact of adjustments to the diagnostic criteria for biochemical remission in surgically treated patients with acromegaly. Growth Hormone and IGF Research, 2017, 36, 16-21.	1.1	1
86	The Prevalence of Tertiary Adrenal Insufficiency in Patients Receiving Topical Glucocorticoid Treatment for Oral Lichen Planus. Journal of the Endocrine Society, 2021, 5, A99-A99.	0.2	1
87	Limited value of the standard 8-hour water deprivation test in the diagnostic work-up of patients with suspected diabetes insipidus. Endocrine Abstracts, 0, , .	0.0	1
88	Increased glucocorticoid replacement doses are associated with excess mortality in patients with non-functioning pituitary adenoma. Endocrine Abstracts, 0, , .	0.0	1
89	The prevalence of oral glucocorticoid use in doses associated with risk of tertiary adrenal insufficiency. Endocrine Abstracts, 0, , .	0.0	1
90	Patients with adrenal insufficiency have cardiovascular features associated with hypovolemia. Endocrine Abstracts, 0, , .	0.0	1

#	Article	IF	CITATIONS
91	α-Adrenoceptor blockers and phaeochromocytoma surgery: outdated combination?. British Journal of Surgery, 2022, 109, 887-888.	0.3	1
92	The urinary cortisol metabolome in patients with adrenal insufficiency: Dual-release hydrocortisone is less deleterious than conventional hydrocortisone therapy. Annales D'Endocrinologie, 2018, 79, 185.	1.4	0
93	MON-330 Cancer Incidence in 1,296 Patients with Acromegaly Is Not Increased: A Nationwide Population-Based Study. Journal of the Endocrine Society, 2020, 4, .	0.2	0
94	MiR-122-5p: A Novel Biomarker of Glucocorticoid Action. Journal of the Endocrine Society, 2021, 5, A89-A89.	0.2	0
95	Headache Before and After Endoscopic Transsphenoidal Pituitary Tumor Surgery: A Prospective Study. Journal of Neurological Surgery, Part B: Skull Base, 0, , .	0.8	0
96	Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome. Endocrine Abstracts, 0, , .	0.0	0
97	Incidence of pituitary adenomas in Western Sweden in 2001–2011. Endocrine Abstracts, 0, , .	0.0	0
98	Patients with Addison's disease have increased frequency of the metabolic syndrome: a case–control study. Endocrine Abstracts, 0, , .	0.0	0
99	Sleep apnea in patients with acromegaly - prevalence, diagnosis and risk factors. Endocrine Abstracts, 0, , .	0.0	0
100	A Phase 3b, open-label, extension study to evaluate the long-term safety of once-daily, dual-release hydrocortisone (DR-HC) in patients with adrenal insufficiency (AI). Endocrine Abstracts, 0, , .	0.0	0
101	Mortality is increased in patients with Cushing's disease in long-term remission: A nation-wide study. Endocrine Abstracts, 0, , .	0.0	0
102	Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing's syndrome. Data from ERCUSYN. Endocrine Abstracts, 0, , .	0.0	0
103	Urinary steroid profile in patients with primary adrenal insufficiency under conventional glucocorticoid replacement: a case control study. Endocrine Abstracts, 0, , .	0.0	0
104	The urinary cortisol metabolome in patients with adrenal insufficiency: dual-release hydrocortisone is less deleterious than conventional hydrocortisone therapy. Endocrine Abstracts, 0, , .	0.0	0
105	Adrenal venous sampling in patients with ACTH-independent Cushing's syndrome. Endocrine Abstracts, 0, , .	0.0	0
106	Salivary cortisol and cortisone in Cushing diagnosis - reference ranges and clinical cut off limits. Endocrine Abstracts, 0, , .	0.0	0
107	MON-431 Clinical Presentation of Metastases to the Pituitary: A Swedish Nationwide Study. Journal of the Endocrine Society, 2019, 3, .	0.2	0
108	SUN-450 Comorbidities in 419 Patients with Cushing's Disease in Remission: A Swedish Nationwide Study. Journal of the Endocrine Society, 2019, 3, .	0.2	0

#	Article	IF	CITATIONS
109	DNA Methylation and fMRI responses in patients with Cushing's syndrome in remission - suggestions of a functional link between hypercortisolism and neurocognitive dysfunction. Endocrine Abstracts, 0, , .	0.0	0
110	Prolonged diagnostic delay in acromegaly is associated with long-term morbidity and excess mortality: data from a nationwide study. Endocrine Abstracts, 0, , .	0.0	0
111	European observational study of ketoconazole for endogenous cushing's syndrome in collaboration with European registry on cushing's syndrome ERCUSYN: PASS ketoconazole study design and rationale. Endocrine Abstracts, 0, , .	0.0	0
112	Carpal tunnel syndrome is common in patients with undiagnosed acromegaly – a swedish nationwide study. Endocrine Abstracts, 0, , .	0.0	0
113	Etiology and extent of impaired quality of life, fatigue and affective, cognitive, and emotional dysfunction in patients with cushing's syndrome – The IQFACE-CS study. Endocrine Abstracts, 0, , .	0.0	0
114	MON-159 High Mortality Rate in Oral Glucocorticoid Users: A Case-Control Study. Journal of the Endocrine Society, 2020, 4, .	0.2	0
115	Response to Letter to the Editor from Singhania et al: "Increasing incidence of primary aldosteronism in Western Sweden during three decades – Yet an underdiagnosed disorderâ€+ Journal of Clinical Endocrinology and Metabolism, 2021, , .	3.6	0
116	High usage of drugs for neuropsychiatric morbidity in patients with CushingÂ's disease before diagnosis and at 55% 10 years following 3% a nationwide study. Endosring Abstracts, 0	0.0	0

diagnosis and at 5–10 years follow-up – a nationwide study. Endocrine Abstracts, 0, , . 116